OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI-IL-7) For Cancer Immunotherapy - Seite 2
The poster: “A novel bifunctional anti-PD-1 / IL-7 fusion protein potentiates effector function of exhausted T cell and disarms Treg suppressive activity” features data validating the therapeutic potential of providing IL-7 signals to overcome PD-1 resistance. Data shows how the bifunctional anti-PD1/IL-7 therapy BiCKI-IL-7 favors the T-cell effector over T-regulatory immune cell balance by stimulating Teff cells and exhausted T-cells, while in parallel disarming Tregs immunosuppressive functions as opposed to IL-2 (and IL-15).
(1) AACR Virtual Annual Meeting II poster details
Bispecific anti-PD1 ChecKpoint Inhibitors antibodies (BiCKI), an optimized platform designed to tackle anti-PD-(L)1 primary and secondary resistance mechanisms
Caroline Mary, Virginie Thepenier, Aurore Morello, Geraldine Teppaz, Margaux Seité, Marion Colonello, Justine Durand, Kevin Biteau, Emmanuelle Wilhelm, Nicolas Poirier
A novel bifunctional anti-PD-1 / IL-7 fusion protein potentiates effector function of exhausted T cell and disarms Treg suppressive activity
Aurore Morello,
Justine Durand, Margaux Seité, Virginie Thepenier, Géraldine Teppaz, Emmanuelle Wilhelm, Sabrina Pengam, Caroline Mary, Nicolas Poirier
(2) Cancer J.; available in PMC 2019 Jan 1.; Mechanisms of Resistance to PD-1 and PD-L1 blockade
Theodore S. Nowicki et al.
Lesen Sie auch
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for
immuno-oncology and autoimmune diseases. The company has several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned
to fight cancer and autoimmune diseases. Its first-in-class clinical and preclinical portfolio has a diversified risk profile:
-
Tedopi (innovative combination of neoepitopes) : the company’s most advanced product ; positive results for Step-1 of the Phase 3 trial (Atalante 1) in
Non-Small Cell Lung Cancer post checkpoint inhibitor failure; due to Covid-19, voluntary definitive suspension of new patient accrual in the Step-2 initially planned in the
trial.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination with checkpoint inhibitor Opdivo. - BI 765063 (OSE-172, anti-SIRPα monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
- FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.
- OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in 2020.
- BiCKI: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity. Additional innovative research programs.
- CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. First preclinical results expected start of H2 2020, possible clinical trial by year end.